HONG KONG – Xi’an, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets.
HONG KONG – Shanghai-based Bioshin Ltd., the Asia-Pacific arm of New Haven, Conn.-based Biohaven Pharmaceutical Holding Co. Ltd., has added $60 million to its war chest via a series A investment.
PERTH, Australia – Regenerative medicine company Mesoblast Ltd. saw its stock drop 37% on the news that it received an FDA complete response letter to its BLA for Ryoncil (remestemcel-L) for the treatment of pediatric steroid-refractory acute graft-vs.-host disease.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Baylx, Carsgen, I-Mab, Innovation, Kyowa Kirin, Medimetriks, Neuren, Organicell, Otsuka, Taigen, Windtree.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Astrazeneca, Corvus, Curevac, Eisai, Enlivex, FSD, Harbour Biomed, Johnson & Johnson, Kancera, Kyowa Kirin, Medincell, Mei, Moderna, Regeneron, Revelation, Revive, Shanghai Junshi, Zai Lab.
In a valuable new deal for Cstone Pharmaceuticals Co. Ltd., Pfizer Inc. is taking a 9.9% stake in the company and licensing exclusive rights to commercialize its lead asset, the anti-PD-L1 antibody sugemalimab, in mainland China.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Allele, Axim, Bone, Casi, Chelation Partners, Cognate Bioservices, Eli Lilly, Evaxion, Fibrogenesis, Fosun, Juventas Cell Therapy, Koligo, Lakes, Lexaria Biosciences, Link Health, Luca Science, Luminarie Canada, Medicure, Moleculin Biotech, Navigo Proteins, Neurorx, Orgenesis, Pharco, Pluristem, Polyphor, R4D, Recce, Reliance Life Sciences, Relief, Repligen, Scancell, Serum Institute of India, Shenzhen Pregene, Sorrento, Taigen, University of Oxford, Vaxxas, Viralclear.
HONG KONG – Shanghai-headquartered Inventisbio Inc. brought in $147 million from a series D funding round to move its main products into phase II trials in the U.S. and China.
RSS
